|
|
News Breaks | | | | February 20, 2013 | | 13:44 EDT |  | EXAS | Exact Sciences shares should be sold, says Maxim
After Exact Sciences reported weaker than expected Q4 results, Maxim notes that the company's FDA submission may be delayed until April, versus the previous March target. The firm thinks the delay provides additional time for competing treatments to gain market share. | |
|
News For EXAS From The Last 14 Days Check below for free stories on EXAS the last two weeks. |
|
|
| There are no results for EXAS |
|
|
|
|
|
|
